H.C. Wainwright & Co.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares, which rallied over 63% Monday following positive results from its pimavanserin in dementia-related psychosis, were seeing further upward momentum Tuesday.  The Analysts H.C. Wainwright & Co. analyst Andrew Fein reiterated a Buy...

Clinical-stage biopharmaceutical company Alzheon is set to begin trading on the Nasdaq Global Market under the ticker symbol “ALZH.” The Details The company intends to raise $35 million in common stock through the sale of 2.5 million shares. Alzheon anticipates an initial share...

Advanced biofuels company Gevo, Inc. (NASDAQ: GEVO) notched an upgrade from H.C. Wainwright Friday that was driven by material company developments and strong growth projections. The Analyst Analyst Amit Dayal upgraded Gevo from Neutral to Buy with a price target of $10. The Thesis Gevo' recent...

Amid “overstated” legal issues and in the aftermath of natural disaster, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) may profit from a positive catalyst this week, according to H.C. Wainwright & Co. Analyst Raghuram Selvaraju reiterated a Neutral rating on the stock with a $17...

On April 10, Oncomed Pharmaceuticals Inc (NASDAQ: OMED) announced demcizumab had missed its primary endpoint in the Phase 2 YOSEMITE trial in pancreatic cancer, while the company’s partner, Bayer, had decided not to opt-in to develop Wnt inhibitors vantictumab and ipafricept. H.C. Wainwright...

Given the current share price for Anthera Pharmaceuticals Inc (NASDAQ: ANTH), H.C. Wainwright’s Andrew S. Fein believes the market appears to have “written off both the lupus and the CF programs.” Fein maintains a Buy rating on the company, while lowering the price target from $10...

H.C. Wainwright’s Corey Davis expressed optimism regarding Cara Therapeutics Inc (NASDAQ: CARA)'s CR845, which could be one of the first kappa opioid receptor agonists that does not enter the central nervous system and therefore has potential to treat peripheral pain without leading to...

On September 27, Galectin Therapeutics Inc (NASDAQ: GALT) announced its Phase 2 NASH-FX trial had failed to achieve both the primary and secondary endpoints. H.C. Wainwright’s Ed Arce downgraded the rating on the company to Neutral while lowering the price target from $8.00 to $1.50....

MicroRNA technology could be just the cure for Mirna Therapeutics Inc (NASDAQ: MIRN) investors who have watched their shares prices decline more than 40 percent since the start of summer. H.C. Wainwright initiated coverage on Mirna Monday with a Buy rating and a $6 price target, implying 135...

H.C. Wainwright’s Swayampakula Ramakanth believes if the VTS gene therapy platform is successfully developed by Vascular Biogenics Ltd (NASDAQ: VBLT), it could revolutionize the multi-billion dollar angiogenesis inhibitor market. Ramakanth initiated coverage of the company with a Buy rating...

H.C. Wainwright & Co. analysts Andrew Fein and Emile Yu have downgraded the shares of United Therapeutics Corporation (NASDAQ: UTHR) to a Neutral rating, pointing out that the scales are tipping the other way. The brokerage also lowered its price objective to $95. "We see no short-term drivers...

H.C. Wainwright’s Swayampakula Ramakanth mentioned that CARDIOME PHARMA CORP (NASDAQ: CRME) “has an experienced in-hospital sales force and is developing a niche business model in the fragmented and difficult-to-operate $100B European hospital pharmacy market.” Ramakanth...

H.C. Wainwright & Co.'s Carol Ann Werther initiated Radius Health Inc (NASDAQ: RDUS) at Buy with a $55.00 price target. The company's lead product candidate is abaloparatide (ABL), which is currently under review in Europe and the United States. "We expect launches in 4Q16 and 1Q17," said...